Noah’s Black Diamond Summit. PHOTO: ARK WEALTH
As global financial landscapes shift, Noah outlines a new AI-first approach to helping families protect and grow their wealth.
Updated
December 11, 2025 11:33 PM
Noah’s Black Diamond Summit. PHOTO: ARK WEALTH
Noah Holdings, one of Asia’s leading wealth management firms serving global Chinese high-net-worth families, hosted its annual Black Diamond Summit in Macau from December 7–11. The city has become a significant gathering place for Noah’s community, where clients, partners, and experts converge each year to explore how global trends are transforming wealth and family life. This year’s theme, “AI Together, Co-Generating the Future”, set the tone for a conversation about how modern wealth management must adapt in an age defined by artificial intelligence.
More than 3,000 attendees joined discussions that connected technology, global mobility, and long-term family planning. The Summit built on earlier sessions held in Shanghai, creating a continuous dialogue around one central question: how can families prepare for a world that is becoming more digital, more complex and more interconnected?
A major moment came when Noah introduced “Noya”, its new AI Relationship Manager. Noya is now part of the upgraded iARK Hong Kong and Singapore apps. It is built to support licensed human advisors, not replace them. The goal is simple: combine human judgment with AI intelligence to help clients understand their wealth more clearly and manage it across borders. Noya offers real-time insights, deeper personalisation, cleaner access to global financial information, smoother coordination between regions, and end-to-end execution through Noah’s global booking centres.
The Summit’s tone shifted toward long-term thinking when Co-Founder and Chairwoman Norah Wang delivered her keynote, “From Chaos to Clarity: Building a Global Operating System for Wealth Management”. She reflected on twenty years of serving more than 400,000 clients and explained that families today face new pressures. As she put it, “The real pain point for Chinese families today is not investment performance, but navigating the growing complexities of a global lifestyle”. Her message was straightforward: wealth is no longer just about returns. It is about managing uncertainty in a world where technology, geopolitics, and mobility collide.
Wang described how two major shifts have shaped modern wealth—first the Internet Era, which changed how people built wealth, and now what she calls the AI Civilisation Era, which is changing how people must protect it. She outlined the forces that influence today’s decisions: geopolitical shifts, persistent inflation, the rising importance of security and supply-chain technologies, the spread of AI, and the need for stronger family governance across generations. Each of these factors adds complexity, and families need tools that help them see the bigger picture.
To respond to this reality, Noah presented its integrated global wealth infrastructure. It is built on three pillars:
Together, these pillars function as an AI-supported system designed to simplify global complexity and help families preserve long-term stability.
One of the most discussed conversations featured Noah’s CEO, Zander Yin, and Tony Shale, Co-Founder & Chairman of Asian Private Banker China. They spoke about how AI is transforming private banking in Asia. Their view was that wealth management is moving from a product-centred model to one led by insight, trust, and human-tech collaboration. AI may accelerate analysis, but human expertise will continue to guide judgment, relationships, and long-term strategy.
The closing message of the Summit centred on redefining what prosperity means in an AI-driven age. For Noah, wealth is no longer a destination. It is an ongoing journey through a world that is increasingly fast-moving and unpredictable. As Wang noted, “With AI reshaping the very foundations of civilisation, wealth and financial freedom represent not a static endpoint, but a continuous journey. Here, we find our purpose: to help global Chinese investors navigate an increasingly complex world and achieve true prosperity, supported by resilient wealth management infrastructure and deep human expertise”.
The Summit ended on that note—a reminder that the future of wealth is not only about financial assets, but about clarity, confidence and the ability to adapt as the world transforms.
Keep Reading
A closer look at how machine intelligence is helping doctors see cancer in an entirely new light.
Updated
November 28, 2025 4:18 PM
Serratia marcescens colonies on BTB agar medium. PHOTO: UNSPLASH
Artificial intelligence is beginning to change how scientists understand cancer at the cellular level. In a new collaboration, Bio-Techne Corporation, a global life sciences tools provider, and Nucleai, an AI company specializing in spatial biology for precision medicine, have unveiled data from the SECOMBIT clinical trial that could reshape how doctors predict cancer treatment outcomes. The results, presented at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting, highlight how AI-powered analysis of tumor environments can reveal which patients are more likely to benefit from specific therapies.
Led in collaboration with Professor Paolo Ascierto of the University of Napoli Federico II and Istituto Nazionale Tumori IRCCS Fondazione Pascale, the study explores how spatial biology — the science of mapping where and how cells interact within tissue — can uncover subtle immune behaviors linked to survival in melanoma patients.
Using Bio-Techne’s COMET platform and a 28-plex multiplex immunofluorescence panel, researchers analyzed 42 pre-treatment biopsies from patients with metastatic melanoma, an advanced stage of skin cancer. Nucleai’s multimodal AI platform integrated these imaging results with pathology and clinical data to trace patterns of immune cell interactions inside tumors.
The findings revealed that therapy sequencing significantly influences immune activity and patient outcomes. Patients who received targeted therapy followed by immunotherapy showed stronger immune activation, marked by higher levels of PD-L1+ CD8 T-cells and ICOS+ CD4 T-cells. Those who began with immunotherapy benefited most when PD-1+ CD8 T-cells engaged closely with PD-L1+ CD4 T-cells along the tumor’s invasive edge. Meanwhile, in patients alternating between targeted and immune treatments, beneficial antigen-presenting cell (APC) and T-cell interactions appeared near tumor margins, whereas macrophage activity in the outer tumor environment pointed to poorer prognosis.
“This study exemplifies how our innovative spatial imaging and analysis workflow can be applied broadly to clinical research to ultimately transform clinical decision-making in immuno-oncology”, said Matt McManus, President of the Diagnostics and Spatial Biology Segment at Bio-Techne.
The collaboration between the two companies underscores how AI and high-plex imaging together can help decode complex biological systems. As Avi Veidman, CEO of Nucleai, explained, “Our multimodal spatial operating system enables integration of high-plex imaging, data and clinical information to identify predictive biomarkers in clinical settings. This collaboration shows how precision medicine products can become more accurate, explainable and differentiated when powered by high-plex spatial proteomics – not limited by low-plex or H&E data alone”.
Dr. Ascierto described the SECOMBIT trial as “a milestone in demonstrating the possible predictive power of spatial biomarkers in patients enrolled in a clinical study”.
The study’s broader message is clear: understanding where immune cells are and how they interact inside a tumor could become just as important as knowing what they are. As AI continues to map these microscopic landscapes, oncology may move closer to genuinely personalized treatment — one patient, and one immune network, at a time.